Griffith & Werner Inc. Makes New Investment in Pfizer Inc. (NYSE:PFE)

Griffith & Werner Inc. acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 102,917 shares of the biopharmaceutical company's stock, valued at approximately $2,730,000. Pfizer comprises about 1.8% of Griffith & Werner Inc.'s investment portfolio, making the stock its 20th biggest position.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the fourth quarter worth $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the fourth quarter worth $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer in the fourth quarter worth $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer in the fourth quarter valued at $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 1.2%

NYSE PFE traded up $0.29 on Tuesday, reaching $23.61. The company had a trading volume of 36,094,645 shares, compared to its average volume of 48,255,164. The firm has a market capitalization of $134.23 billion, a price-to-earnings ratio of 16.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company's fifty day moving average is $23.33 and its 200-day moving average is $25.13.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the business posted $0.82 EPS. The company's quarterly revenue was down 7.8% on a year-over-year basis. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.29%. Pfizer's dividend payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.